Please login to the form below

Not currently logged in
Email:
Password:

QMF149

This page shows the latest QMF149 news and features for those working in and with pharma, biotech and healthcare.

Novartis reveals full phase 3 results for Enerzair Breezhaler

Novartis reveals full phase 3 results for Enerzair Breezhaler

function compared to treatment with once-daily QMF149  (indacaterol acetate and mometasone furoate). ... The overall occurrence of adverse events and serious adverse events for both Enerzair Breezhaler and QMF149 in the study were generally low and

Latest news

  • Novartis strengthens case for its combination asthma drug Novartis strengthens case for its combination asthma drug

    The  asthma combination regimen, QMF149, is a once-daily fixed-dose combination of indacaterol acetate and mometasone furoate. ... QMF149 also met the secondary endpoint of the study, demonstrating a statistically significant improvement in asthma

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Page & Page and Partners

For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....